A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3
Completed
NCT03524092
| Condition | Ulcerative Colitis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 1,328 participants |
|---|
| Interventions | Mirikizumab SC, Mirikizumab IV, Placebo SC |
|---|
| Start date | Oct 19, 2018 |
|---|
| Completion date | Nov 3, 2021 |
|---|
| Results posted | Nov 25, 2022 |
|---|
Summary
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)
Week 40 · percentage of participants
| Maintenance Period: Miri IR - PBO SC | 25.1 percentage of participants |
|---|
| Maintenance Period: Miri IR - 200 mg Miri SC | 49.9 percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Risk Difference (RD) | 23.2 (95% CI 15.2–31.2) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.